In the subcutaneous MC38 colon carcinoma model, mice treated with mAWT020 (1 mg/kg, twice-weekly, or biw) demonstrated a significant reduction in tumor size compared to those treated with anti-mPD-1 (αmPD1), half-life extended IL-2c (HSA-IL-2c), or the combination of αmPD1 and HSA-IL-2c. Here, AMPD1 is linked to neoplasm.